SCHEMBL5469409

SCHEMBL5469409

O=C1Nc2ccccc2/C1=C/c1ccc(F)c(F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.73
PDGFRB P09619 4/20 0.64
PLK4 O00444 2/20 0.64
PLK1 P53350 2/20 0.64
NPC1 O15118 2/20 0.64
RET P07949 1/20 0.64
FLT3 P36888 1/20 0.64
APP P05067 4/20 0.59
MAPT P10636 4/20 0.59
SNCA P37840 4/20 0.59
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPK1 P28482 2/20 0.59
KMT2A Q03164 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
CTRC Q99895 2/20 0.59
ERBB2 P04626 2/20 0.59
GMNN O75496 1/20 0.59
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469417 1.00 KDR (0.73) KDRPDGFRBPLK4PLK1NPC1
SCHEMBL14674269 0.85 FLT3 (0.64) KDRPDGFRBFLT3MEN1KMT2A
SCHEMBL14674268 0.85 FLT3 (0.64) KDRPDGFRBFLT3MEN1KMT2A
SCHEMBL29638277 0.85 FLT3 (0.64) KDRPDGFRBFLT3MEN1KMT2A
SCHEMBL5475545 0.84 KDR (1.00) KDRPDGFRBPLK4PLK1NPC1
SCHEMBL29903234 0.84 KDR (1.00) KDRPDGFRBPLK4PLK1NPC1
SCHEMBL16442342 0.84 KDR (1.00) KDRPDGFRBPLK4PLK1NPC1
SCHEMBL5475546 0.84 KDR (1.00) KDRPDGFRBPLK4PLK1NPC1
SCHEMBL14674528 0.84 LRRK2 (0.61) KDRPDGFRBPSEN1PSEN2APH1B
SCHEMBL14674288 0.84 LRRK2 (0.76) PDGFRBERBB2EGFRPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 KDR 4334/4885PDGFRB 4421/4885PLK4 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.